2025 ESMO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ESMO 2025. Highlights in this video include: KEYNOTE 905: cisplatin-ineligible MIBC: Perioperative EV+P improved EFS (HR 0.40; 0.28-0.57) and OS (HR 0.50; 0.33-0.74) relative to cystectomy IMVIGOR011: ctDNA (+) MIBC: adjuvant atezo improved DFS (HR 0.64; 0.47-0.87) and OS (HR 0.59; 0.39-0.90) relative to placebo RC48-C016: 1L HER2+ mUC: Disitamab Vedotin (HER2 ADC) plus Toripalimab (PD1) improved PFS (HR 0.36; 0.28-0.46) and OS (HR 0.54; 0.41-0.73) relative to gemcitabine+platinum